研发新一代侵入式柔性脑机接口平台、总部位于北京海淀的硬科技企业智冉医疗近日宣布完成超3亿元 A轮融资。本轮融资由社保基金中关村自主创新专项基金（君联资本担任管理人）、君联资本、IDG资 本联合领投，老股东元生创投持续大额加注，国寿资本、北京市医药健康产业投资基金、联想创投及老 股东美团龙珠、BV百度风投跟投，所募资金将主要用于加速推进新一代技术研发及开展大规模临床试 验。 智冉医疗总部位于海淀区，公司创始人兼首席科学家方英为北京脑科学与类脑研究所研究员、科技部脑 专项"神经记录与调控新技术平台"牵头人，长期从事柔性高通量电极与神经记录调控研究，创始人兼首 席执行官宋麒为连续创业者，曾任国内AI医疗头部企业创始人、CEO，主导国内首张AI医疗三类证的 临床转化与注册工作。自2022年成立以来，该团队获得了资本市场对其技术路线与商业化前景的认可， 已融资近5亿元。 来源：北京日报客户端 记者：孙奇茹 脑机接口（BCI）概念由来已久，但近年才引发广泛关注，其核心原因在于高带宽的人机交互从理论走 向现实。而成就这一里程碑的"密钥"，便是侵入式脑机接口技术。相较于非侵入式、半侵入式等技术路 线，侵入式脑机接口在高通量、 ...

Core Viewpoint - Beijing Zhirun Medical Technology Co., Ltd. has completed over 300 million RMB in Series A financing, indicating strong market recognition of its technology and commercialization prospects [3] Group 1: Company Overview - Zhirun Medical focuses on developing a next-generation invasive flexible brain-computer interface (BCI) platform, aiming to revolutionize human-machine interaction [4][5] - Since its establishment in 2022, Zhirun Medical has raised nearly 500 million RMB in total funding, reflecting significant investor confidence in its technological direction [3] Group 2: Technology and Innovation - The invasive BCI technology is gaining attention due to its high bandwidth capabilities, which surpass non-invasive and semi-invasive methods in signal acquisition and neural control [5] - Zhirun Medical has chosen the challenging invasive technology route, similar to Elon Musk's Neuralink, based on a deep understanding of BCI technology's essence [5][6] Group 3: Key Technical Developments - The core of invasive BCI development lies in electrode technology, with Zhirun Medical pioneering high-throughput flexible electrodes that have received patent authorization in both China and the U.S. [7] - The company's innovative design addresses electrode displacement issues, significantly reducing inflammation and ensuring long-term signal stability [7][10] Group 4: Strategic Positioning and Future Plans - Zhirun Medical has established a complete closed-loop system from R&D to large-scale production, ensuring full control over clinical-grade products [10] - The company is well-positioned to leverage recent government policies aimed at promoting BCI industry innovation, aligning its strategy with national objectives [10][11] Group 5: Market Potential and Investor Sentiment - Investors express strong confidence in the commercial potential of invasive BCI technology, highlighting Zhirun Medical's unique position in the market and its comprehensive approach to technology development [11][12] - The company is seen as a leading contender in the BCI field, with expectations for its technology to address unmet medical needs and expand into various applications [11][12][12]